Optimize.health, formerly called Pillsy, raises $15.6M for its end-to-end remote patient monitoring service, says its revenue recently increased by 800%+ YoY
Taylor Soper / GeekWire :
Context & Ripple Effects
Optimize.health's raise lands mid-arc in a funding wave for tools that move care out of clinics: Health Recovery Solutions pulled in $10M in 2019 for health-system remote monitoring, and Xealth raised an $11M Series A to let providers prescribe devices and apps alongside drugs. The rebrand from Pillsy signals the company is positioning beyond its medication-adherence roots as an end-to-end monitoring vendor.
The growth claim also sets a benchmark others quickly beat: within months, Current Health raised a $43M Series B on a reported 3,000% YoY revenue jump, showing investors rewarding hypergrowth in this category specifically.
First-order effects
- Optimize.health gets $15.6M to scale its end-to-end remote patient monitoring service at a moment when its revenue is up more than 800% YoY, putting it in direct competition with Health Recovery Solutions and Current Health for health-system deployments.
Second-order effects
- Distribution platforms like Xealth, which already lets providers order insulin monitors and other devices as prescriptions, become natural channel partners — or consolidation targets — for monitoring vendors racing to reach health systems.
- Telehealth infrastructure players such as Truepill, which raised $142M weeks later, face pressure to bundle monitoring and prescription delivery so virtual-first providers can offer continuous rather than episodic care.
Third-order effects
- If the pattern holds, remote patient monitoring hardens into a distinct venture-funded layer of healthcare — separate from telehealth visits — where health systems procure end-to-end vendors and fundraising rounds are justified by triple-digit revenue growth rather than pilots.
The trend: Remote patient monitoring is emerging as its own capital-intensive category inside digital health, with revenue-hypergrowth claims becoming the currency that separates fundable vendors from pilot-stage ones.